Drug combination boosts survival rate in head and neck cancers

May 14, 2005

ORLANDO, Fla.--Adding a third drug to a standard chemotherapy combination can dramatically improve the survival of patients with advanced head and neck cancer, according to a study led by researchers at Dana-Farber Cancer Institute in Boston. The findings will be presented at the American Society of Clinical Oncology's annual meeting.

Previous studies have shown that using combination chemotherapy of cisplatin and 5-fu yields a 25 to 50 percent rate of complete pathological responses (the tumor disappeared). Robert Haddad, MD, and his colleagues found that adding the drug docetaxel (Taxotere) to the cisplatin and 5-fu regimen significantly increased the complete pathological response rate to 89 percent. The data (Abstract 5511) will be presented as a poster discussion session on Saturday, May 14, at 1 p.m., Level 4, 414.

Using data obtained from treating 72 patients with locally advanced squamous cell carcinoma of the head and neck, the researchers project that the three-drug combination would result in a 95 percent two-year survival rate and a 90 percent five-year survival rate. The majority of these patients have stage IV disease.

"These results are very encouraging and in all likelihood will translate into a significantly more effective treatment for patients with advanced head and neck cancer," says Haddad. "This patient population historically has had a poor prognosis, but, given these findings, the outlook is more hopeful."

The drug combination is given for three cycles as an initial treatment, known as induction chemotherapy, to shrink tumors prior to several weeks of intense treatment with additional chemotherapy given along with radiation. This "sequential therapy" has brought about the most successful results in patients with these stubborn cancers. Cancers of the head and neck are diagnosed in more than 40,000 people in the United States each year, with about 7,200 deaths.

Based on recent results of Phase III trials of the therapy and on the new data, Haddad, who is also an assistant professor at Harvard Medical School, and his colleagues propose that the three-drug combination be used as the new platform when using induction chemotherapy.
-end-
In addition to Haddad, the study's other authors are Lori Wirth, MD, Charles Norris, Jr., MD, Marshall Posner, MD, Yi Li, PhD, and Lindsey O'Donnell, Dana-Farber; Roy Tishler, MD, Brigham and Women's Hospital; Laura Goguen, MD, Joint Center for Otolaryngology; and Christopher Sullivan, MD, formerly of Dana-Farber and now at Wake Forest University Baptist Medical Center.

Dana-Farber Cancer Institute (www.danafarber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.

Dana-Farber Cancer Institute

Related Neck Cancer Articles from Brightsurf:

Head and neck cancer patients benefited from Affordable Care Act
The rate of uninsured patients with head and neck cancers was 'significantly reduced' following the implementation of the federal Patient Protection and Affordable Care Act (ACA).

Insurance coverage among patients with head/neck cancer after ACA
Researchers investigated the association between the Affordable Care Act and changes in the percentage of patients with insurance among 130,000 people with head and neck cancer across varying socioeconomic and demographic backgrounds.

Skin cancer above the neck more likely to spread, research shows
Forty-five patients with new diagnoses of MM were investigated over a period of 6 months and were divided into two groups of patients, with above neck MM and below neck MM.

How cigarette smoke makes head and neck cancer more aggressive
A change in the tumor metabolism due to tobacco exposure could open new treatment avenues in head and neck cancer.

Testing therapies on mini-tumors of head and neck cancer
Head and neck cancer is an aggressive type of cancer that often recurs, despite patients undergoing harsh treatments.

Comparing financial burdens of head and neck cancer with other cancers
Head and neck cancer is expensive to treat and the disease can create long-term health needs.

Opioid use and misuse following treatment for head and neck cancer
Six months after treatment ended, 7 percent of patients remained on opioid pain medications.

Study: Immunotherapy better than chemotherapy for subtype of head and neck cancer
A randomized clinical trial involving 97 medical centers in 20 countries, including Moores Cancer Center at UC San Diego Health, found that treating patients with head and neck cancer with the immunotherapy drug pembrolizumab is more effective and less toxic than standard chemotherapy.

Immunotherapy keeps some advanced head and neck cancer patients alive for over three years
A new immunotherapy can greatly extend the lives of a proportion of people with advanced head and neck cancer, with some living for three years or more, a major new clinical trial reports.

Head and neck cancer survivors at increased risk of suicide
Despite improved survival rates among cancer patients, the risk of death by suicide remains high, especially among those treated for head and neck cancers.

Read More: Neck Cancer News and Neck Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.